Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Astex Pharmaceuticals Inc Issues FY 2013 Revenue Guidance Below Analysts' Estimates; Issues FY 2013 Earnings Guidance Above Analysts' Estimates
Astex Pharmaceuticals Inc announced that for fiscal 2013, it expects total revenues of $55 million, net loss of $30 million and net loss per average share outstanding of $(0.32). According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $67 million, net income of $(40) million and EPS of $(0.20) for fiscal 2013.
Latest Developments for Astex Pharmaceuticals Inc
Latest Key Developments in Biotechnology
- Apricus Biosciences Inc Prices $17.1 Million Public Offering Of Common Stock And Warrants
- Stemline Therapeutics Inc Announces Exercise Of Option To Purchase Additional Shares
- Omeros Corp Announces Clearence Of New Drug Application By FDA For OMS824 In Huntington's Disease
- Miraca Holdings Inc Appoints Corporate Auditor
- Share this
- Link this
- Digg this
Follow Reuters